Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines

IntroductionCertain HLA variants are associated with an increased risk of hypersensitivity reactions to specific drugs. Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued actionable HLA gene – drug interaction guideline...

Full description

Bibliographic Details
Main Authors: Lisanne E. N. Manson, Jesse J. Swen, Henk-Jan Guchelaar
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.567048/full
id doaj-d0497354c08249898fddcf8118e7ae7c
record_format Article
spelling doaj-d0497354c08249898fddcf8118e7ae7c2020-11-25T02:50:30ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-09-011110.3389/fphar.2020.567048567048Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG GuidelinesLisanne E. N. Manson0Lisanne E. N. Manson1Jesse J. Swen2Jesse J. Swen3Henk-Jan Guchelaar4Henk-Jan Guchelaar5Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, NetherlandsLeiden Network for Personalized Therapeutics, Leiden, NetherlandsDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, NetherlandsLeiden Network for Personalized Therapeutics, Leiden, NetherlandsDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, NetherlandsLeiden Network for Personalized Therapeutics, Leiden, NetherlandsIntroductionCertain HLA variants are associated with an increased risk of hypersensitivity reactions to specific drugs. Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued actionable HLA gene – drug interaction guidelines but diagnostic test criteria remain largely unknown. We present an overview of the diagnostic test criteria of the actionable HLA – drug pairs.MethodsA systematic literature search was conducted in PubMed, Embase, Web of Science and Cochrane Library. Original case-control and cohort studies were selected and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and number needed to genotype (NNG) were calculated for the actionable HLA-drug pairs.ResultsIn general, the HLA tests show high specificity and NPV for predicting hypersensitivity reactions. The sensitivity of HLA tests shows a wide range, from 0-33% for HLA-B*1502 testing to predict lamotrigine induced SJS/TEN up to 100% for HLA-B*5701 to predict immunologically confirmed abacavir hypersensitivity syndrome (ABC-HSR). PPV is low for all tests except for HLA-B*5701 and ABC-HSR which is approximately 50%. HLA-B*5701 to predict ABC-HSR shows the lowest NNG followed by HLA-B*5801 for allopurinol induced severe cutaneous adverse drug reactions and HLA-B*1502 for carbamazepine induced SJS/TEN.DiscussionThis is the first overview of diagnostic test criteria for actionable HLA-drug pairs. Studies researching HLA genes and hypersensitivity are scarce for some of the HLA-drug pairs in some populations and patient numbers in studies are small. Therefore, more research is necessary to calculate the diagnostic test criteria more accurately.https://www.frontiersin.org/article/10.3389/fphar.2020.567048/fullHLA genespharmacogenomicshypersensitivityantiepileptic drugsabacavirallopurinol
collection DOAJ
language English
format Article
sources DOAJ
author Lisanne E. N. Manson
Lisanne E. N. Manson
Jesse J. Swen
Jesse J. Swen
Henk-Jan Guchelaar
Henk-Jan Guchelaar
spellingShingle Lisanne E. N. Manson
Lisanne E. N. Manson
Jesse J. Swen
Jesse J. Swen
Henk-Jan Guchelaar
Henk-Jan Guchelaar
Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
Frontiers in Pharmacology
HLA genes
pharmacogenomics
hypersensitivity
antiepileptic drugs
abacavir
allopurinol
author_facet Lisanne E. N. Manson
Lisanne E. N. Manson
Jesse J. Swen
Jesse J. Swen
Henk-Jan Guchelaar
Henk-Jan Guchelaar
author_sort Lisanne E. N. Manson
title Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
title_short Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
title_full Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
title_fullStr Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
title_full_unstemmed Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
title_sort diagnostic test criteria for hla genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable hla recommendations in cpic and dpwg guidelines
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-09-01
description IntroductionCertain HLA variants are associated with an increased risk of hypersensitivity reactions to specific drugs. Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) have issued actionable HLA gene – drug interaction guidelines but diagnostic test criteria remain largely unknown. We present an overview of the diagnostic test criteria of the actionable HLA – drug pairs.MethodsA systematic literature search was conducted in PubMed, Embase, Web of Science and Cochrane Library. Original case-control and cohort studies were selected and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and number needed to genotype (NNG) were calculated for the actionable HLA-drug pairs.ResultsIn general, the HLA tests show high specificity and NPV for predicting hypersensitivity reactions. The sensitivity of HLA tests shows a wide range, from 0-33% for HLA-B*1502 testing to predict lamotrigine induced SJS/TEN up to 100% for HLA-B*5701 to predict immunologically confirmed abacavir hypersensitivity syndrome (ABC-HSR). PPV is low for all tests except for HLA-B*5701 and ABC-HSR which is approximately 50%. HLA-B*5701 to predict ABC-HSR shows the lowest NNG followed by HLA-B*5801 for allopurinol induced severe cutaneous adverse drug reactions and HLA-B*1502 for carbamazepine induced SJS/TEN.DiscussionThis is the first overview of diagnostic test criteria for actionable HLA-drug pairs. Studies researching HLA genes and hypersensitivity are scarce for some of the HLA-drug pairs in some populations and patient numbers in studies are small. Therefore, more research is necessary to calculate the diagnostic test criteria more accurately.
topic HLA genes
pharmacogenomics
hypersensitivity
antiepileptic drugs
abacavir
allopurinol
url https://www.frontiersin.org/article/10.3389/fphar.2020.567048/full
work_keys_str_mv AT lisanneenmanson diagnostictestcriteriaforhlagenotypingtopreventdrughypersensitivityreactionsasystematicreviewofactionablehlarecommendationsincpicanddpwgguidelines
AT lisanneenmanson diagnostictestcriteriaforhlagenotypingtopreventdrughypersensitivityreactionsasystematicreviewofactionablehlarecommendationsincpicanddpwgguidelines
AT jessejswen diagnostictestcriteriaforhlagenotypingtopreventdrughypersensitivityreactionsasystematicreviewofactionablehlarecommendationsincpicanddpwgguidelines
AT jessejswen diagnostictestcriteriaforhlagenotypingtopreventdrughypersensitivityreactionsasystematicreviewofactionablehlarecommendationsincpicanddpwgguidelines
AT henkjanguchelaar diagnostictestcriteriaforhlagenotypingtopreventdrughypersensitivityreactionsasystematicreviewofactionablehlarecommendationsincpicanddpwgguidelines
AT henkjanguchelaar diagnostictestcriteriaforhlagenotypingtopreventdrughypersensitivityreactionsasystematicreviewofactionablehlarecommendationsincpicanddpwgguidelines
_version_ 1724738175357681664